Capricor is rated Sell. FDA concerns put deramiocel approval odds at 10%-15%, with a new trial likely and over 50% downside. See more on CAPR here.

Hyliion shares fell 4.8%; its Q3 report cited rising KARNO Power Module interest across military, data-center, commercial and ...

CoreWeave was in the spotlight on Wednesday as Wall Street firms praised the neocloud provider's third-quarter results and ...

I wrote about NVDA in mid-August, rating it as a Buy ahead of its then-upcoming Q2 FY2027, and today, we're now one week away ...

Micron shares trade at a 54.5% discount to intrinsic value, with near-term volatility likely. Read here for a detailed ...

Cisco's AI-related revenue is expected to reach $7.5 billion in FY2027, now representing about 10% of total sales. Read why CSCO stock is upgraded to Buy.

On a year-over-year basis, 94.5% of the Alerian Midstream Energy Index, by weighting, has grown its dividends. Read more here.

The United States' trade deficit with China has increased since the Liberation Day tariff announcement. Read more here.

Nine financial stocks with Buy or Strong Buy Quant Ratings are down 2.05%-14.82% YTD; Munich Re has the top rating at 4.73.

Northwest Bancshares' deposit growth, low uninsured deposit exposure, and diversified loan portfolio support a robust balance sheet. Read why NWBI stock is a Buy.

Information technology stocks have faced significant pressure this year, with several software companies recording declines ...